On Thursday, Following U.S. Stocks were among the “Top Gainers”: SUMMIT MATERIALS, INC. (NYSE:SUM), Inventergy Global, Inc. (NASDAQ:INVT), Epizyme, Inc. (NASDAQ:EPZM), Emerald Oil, Inc. (NYSEMKT:EOX)

SUMMIT MATERIALS, INC. (SUM), with shares inclined 16.50%, closed at $20.97.

Inventergy Global Inc(NASDAQ:INVT), with shares jumped 17.17%, settled at $0.750.

Epizyme Inc(NASDAQ:EPZM), with shares climbed 14.74%, and closed at $25.45.

Emerald Oil Inc (NYSEMKT:EOX), surged 14.27%, and closed at $1.04.

Latest NEWS regarding these Stocks are depicted underneath:

SUMMIT MATERIALS, INC. (NYSE:SUM)

SUMMIT MATERIALS, INC. (SUM), declared the pricing of its initial public offering of 22,222,222 shares of its Class A ordinary stock at a price to the public of $18.00 per share. Summit Materials has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of Class A ordinary stock. The shares are predictable to start trading on the New York Stock Exchange on March 12, 2015 under the ticker symbol “SUM.” The offering is predictable to close on March 17, 2015, subject to customary closing conditions.

Summit Materials intends to use the net proceeds from the offering primarily to, among other things, repay certain indebtedness.

Citigroup, Goldman, Sachs & Co., BofA Merrill Lynch, Barclays, Deutsche Bank Securities and RBC Capital Markets are acting as joint bookrunners of the offering. BB&T Capital Markets, Stephens Inc., Sterne Agee and Stifel are acting as co-managers. The offering of these securities is being made only by means of a prospectus.

Summit Materials is a leading vertically integrated construction materials corporation that supplies aggregates, cement, ready-mix concrete and asphalt in the United States and western Canada.

Inventergy Global, Inc. (NASDAQ:INVT)

Analyst report issued by Small Cap IR. Inventergy Global, Inc. (INVT), an intellectual property (IP) corporation, which finds, invests in, buys, and licenses patented technologies, is a compelling idea and very attractive stock. The corporation has seasoned administration who are recognized in the industry as world leading intellectual property (IP) strategists. The corporation is a well-known leader in the IP space and has large number of patents that it has attained. IP is highly valued in the corporate world and a number of high value transactions (like Google’s $12.5 Billion Motorola Mobility Attainment) have recently happened because of IP. As of 2010, 80% of S&P 500 market value was comprised of Intangible Assets, contrast to 17% in 1975.

Inventergy has invested in a number of telecom areas like 3G, 3G Femtocell, 4G and IMS. As the corporation continues to augment its patent library from attainments, such as those from Huawei, Panasonic, and Nokia, the corporation strengthens its presence and leadership in planned telecom segments. The position creates a noteworthy profit opportunity for Inventergy and its shareholders, both near term and long term.

Inventergy Global, Inc., an intellectual property (IP) corporation, identifies, invests in, attains, and licenses patented technologies. It is engaged in structuring an IP licensing and value creation strategy for particular assets; applying IP and business expertise and best practices; leveraging industry relationships; accessing industry resources; and determining value of IP.

Epizyme, Inc. (NASDAQ:EPZM)

Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical corporation creating novel epigenetic therapeutics for cancer patients, stated business highlights and operating and financial results for 2014. In addition, the Corporation highlighted forthcoming milestones.

Forthcoming Milestones:

EPZ-6438:

Updated data from the Phase 1 dose escalation study in patients with B-cell lymphomas or advanced solid tumors to be revealed at a medical meeting in mid-2015

Data from the Phase 1 expansion cohorts to be revealed at a medical meeting before the end of 2015

Predictable initiation of a five-arm Phase 2 clinical study in NHL patients in Europe in the second quarter of 2015

Predictable initiation of a Phase 1 clinical study in pediatric INI1-deficient tumor patients in the second half of 2015

Predictable initiation of a Phase 2 clinical study in adult INI1-deficient tumor patients in the second half of 2015

Data predictable from the first two arms of the Phase 2 NHL study in mid-2016 (germinal center DLBCL with wild-type EZH2 and non-germinal center DLBCL)

EPZ-5676:

Data from the 54 mg/m2 expansion cohort in adult acute leukemia patients to be revealed before the end of 2015.

Predictable completion of enrollment in Phase 1 study in pediatric acute leukemia patients in the second half of 2015.

Pipeline:

Presentation of discovery research on pipeline HMT targets at AACR annual meeting in April 2015: CARM1, SETDB1, SMYD3 and PRMT6.

Epizyme, Inc. is a clinical stage biopharmaceutical corporation creating novel epigenetic therapeutics for cancer patients. Epizyme has built a proprietary product platform that the Corporation uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs.

Epizyme, Inc., a clinical stage biopharmaceutical corporation, discovers and develops personalized therapeutics for patients with genetically defined cancers.

Emerald Oil, Inc. (NYSEMKT:EOX)

Emerald Oil, Inc. (EOX), declared financial and operational results for the quarter and year ended December 31, 2014.

Highlights:

• Raised fourth quarter production to 377,250 BOE, an average of about 4,101 BOEPD, an raise of 7% contrast to the third quarter of 2014 and 71% contrast to the fourth quarter of 2013;
• Raised annual production to 1,295,230 BOE, an average of 3,549 BOEPD, an raise of 110% contrast to 2013;
• Raised total proved reserves to 26.3 MMBOE, an raise of 99% contrast to 2013;
• Raised oil and natural gas sales to $101.2 million in 2014, an raise of 87% contrast to 2013;
• Adjusted EBITDA of $15.0 million or $0.23 per share (basic) for the fourth quarter of 2014 and $56.8 million or $0.85 per share (basic) for 2014, and;
• Adjusted Net Revenue attributable to ordinary shareholders of $2.0 million or $0.03 per share (basic) for the fourth quarter of 2014 and $16.8 million or $0.25 per share (basic) for the year 2014.

Emerald Oil, Inc. operates as an independent oil and natural gas exploration and production corporation in the United States. The corporation designs, drills, and operates oil and natural gas wells.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.